Literature DB >> 17947393

ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2.

Roland B Walter1, Brian W Raden, Rong Zeng, Peter Häusermann, Irwin D Bernstein, Jonathan A Cooper.   

Abstract

The leukocyte CD33-related sialic acid-binding Ig-like lectins (Siglecs) are implicated in glycan recognition and host defense against and pathogenicity of sialylated pathogens. Recent studies have shown endocytosis by CD33-related Siglecs, which is implicated in clearance of sialylated antigens and antigen presentation and makes targeted immunotherapy possible. Using CD33 as a paradigm, we have now investigated the reasons underlying the comparatively slow rate of endocytosis of these receptors. We show that endocytosis is largely limited and determined by the intracellular domain while the extracellular and transmembrane domains play a minor role. Tyrosine phosphorylation, most likely through Src family kinases, increases uptake of CD33 depending on the integrity of the two cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Simultaneous depletion of the protein tyrosine phosphatases, Src homology-2-containing tyrosine phosphatase 1 (Shp1) and Shp2, which bind to phosphorylated CD33, increases internalization of CD33 slightly in some cell lines, whereas depletion of spleen tyrosine kinase (Syk) has no effect, implying that Shp1 and Shp2 can dephosphorylate the ITIMs or mask binding of the phosphorylated ITIMs to an endocytic adaptor. Our studies show that restraint of CD33 internalization through the intracellular domain is relieved partly when the ITIMs are phosphorylated and show that Shp1 and Shp2 can modulate this process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947393     DOI: 10.1189/jlb.0607388

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  28 in total

1.  Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

2.  Enhanced lentiviral vector production in 293FT cells expressing Siglec-9.

Authors:  Toru Shoji; Hiroshi Higuchi; Yoshinori Zaitsu; Ken-Ichi Nishijima; Shinji Iijima
Journal:  Cytotechnology       Date:  2014-01-25       Impact factor: 2.058

Review 3.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

4.  Human NK Cells Downregulate Zap70 and Syk in Response to Prolonged Activation or DNA Damage.

Authors:  Jason L Pugh; Neda Nemat-Gorgani; Paul J Norman; Lisbeth A Guethlein; Peter Parham
Journal:  J Immunol       Date:  2017-12-20       Impact factor: 5.422

5.  The Alzheimer's disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool.

Authors:  Shoib S Siddiqui; Stevan A Springer; Andrea Verhagen; Venkatasubramaniam Sundaramurthy; Frederico Alisson-Silva; Weiping Jiang; Pradipta Ghosh; Ajit Varki
Journal:  J Biol Chem       Date:  2017-07-26       Impact factor: 5.157

Review 6.  Siglecs and immune regulation.

Authors:  Shiv Pillai; Ilka Arun Netravali; Annaiah Cariappa; Hamid Mattoo
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

Review 7.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

8.  ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model.

Authors:  Sargur Madabushi Srideshikan; Jamison Brooks; Darren Zuro; Bijender Kumar; James Sanchez; Liliana Echavarria Parra; Marvin Orellana; Paresh Vishwasrao; Indu Nair; Junie Chea; Kofi Poku; Nicole Bowles; Aaron Miller; Todd Ebner; Justin Molnar; Joseph Rosenthal; Daniel A Vallera; Jeffrey Y C Wong; Anthony S Stein; David Colcher; John E Shively; Paul J Yazaki; Susanta K Hui
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

Review 9.  Siglecs as targets for therapy in immune-cell-mediated disease.

Authors:  Mary K O'Reilly; James C Paulson
Journal:  Trends Pharmacol Sci       Date:  2009-04-07       Impact factor: 14.819

Review 10.  CD33 in Alzheimer's disease.

Authors:  Teng Jiang; Jin-Tai Yu; Nan Hu; Meng-Shan Tan; Xi-Chen Zhu; Lan Tan
Journal:  Mol Neurobiol       Date:  2013-08-28       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.